|
| |
TelikTelik, Inc. (Nasdaq: TELK) of Palo Alto, CA is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. Our most advanced development candidate is TELCYTA™ (TLK286), a novel cancer cell-activated chemotherapeutic currently in four Phase 3 registration trials in advanced ovarian cancer and non-small cell lung cancer. A second development candidate, TELINTRA™ (TLK199), is in a Phase 2 clinical trial in myelodysplastic syndrome and may also have utility in the treatment of additional blood disorders characterized by low levels of blood cells.
We developed our product candidates through the use of our proprietary TRAP™ technology, which enables the rapid and efficient discovery of small molecule drug candidates. In addition to our internal drug development programs, we partner with select academic institutions and pharmaceutical and biotechnology companies to apply TRAP™ to new drug development programs for a range of diseases.
We intend to commercialize our cancer products in North America, and to partner with multinational pharmaceutical companies to assist in the commercialization of our cancer products in other territories.
| Contact Details: |
| 3165 Porter Drive |
| Palo Alto |
| CA |
| 94304 |
| United States of America |
| Tel: | 650-845-7700 |
| Fax: | 650-845-7800 |
| Email: | inquiry@telik.com |
| WWW: | www.Telik.com/
|
|
Loading...
|
Recent Publications by Telik: |  |
Antitumor efficacy and molecular mechanism of TLK58747, a novel DNA-alkylating prodrug.
BACKGROUND: DNA-damaging agents are widely used for the treatment of human... | 23rd October, 2009
| Telik, Inc., Palo Alto, CA 94304, USA.
| Anticancer Res. 2009 Oct;29(10):3845-55.
|
Efficient Synthesis of Trisubstituted Pyrazoles and Isoxazoles Using a Traceless "Catch and Release" Solid-Phase Strategy.
An efficient three-component, two-step "catch and release" solid-phase... | 23rd May, 2009
| Department of Chemistry, Telik, Inc., 3165 Porter Drive, Palo Alto,
| J Comb Chem. 2009 May 21.
DOI Direct Link |
Design, synthesis, and structure-activity relationships of novel insulin receptor tyrosine kinase activators.
A novel series of symmetrical ureas of... | 31st October, 2008
| Telik, Inc., 3165 Porter Drive, Palo Alto, California 94304, USA.
| J Med Chem. 2008 Oct 9;51(19):6173-87. Epub 2008 Sep 13.
DOI Direct Link |
5-Substituted isophthalamides as insulin receptor sensitizers.
A novel series of 5-substituted isophthalamides and their... | 30th August, 2008
| Telik, Inc., 3165 Porter Drive., Palo Alto, CA 94304, USA.
| Bioorg Med Chem Lett. 2008 Jun 15;18(12):3492-4. Epub 2008 May 15.
DOI Direct Link |
Shapes of things: computer modeling of molecular shape in drug discovery.
We review recent advances in computer modeling of molecular shape in drug... | 14th November, 2007
| Telik, Inc., 3165 Porter Dr., Palo Alto, CA 94304, USA.
| Curr Top Med Chem. 2007;7(15):1514-24.
|
→View more Telik research publications. |
Press Releases on Telik:
|
 |
| Telik Announces Third Quarter 2009 Financial Results |
13th November, 2009 |
Telik, Inc. |
PALO ALTO, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $6.1 million, or $0.11 per share, for the third quarter ended September 30, 2009, compared
|
| Reportlinker Adds Competitor Analysis: VEGF and VEGF-R Agonists and Antagonists |
16th October, 2009 |
Reportlinker |
-- additional comments with a hyperlink leading to the source of
information.
Index
-- 2008 Sales of VEGF/R Antagonists
-- VEGF-R Agonists
-- Cardiovascular
|
| Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer |
1st October, 2009 |
Telik, Inc. |
PALO ALTO, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in
|
| Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference |
15th September, 2009 |
Telik, Inc. |
PALO ALTO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that company management will provide a corporate overview at the UBS Global Life Sciences Conference in
|
| Telik Announces Presentation at ASCO Annual Meeting |
21st May, 2009 |
Telik, Inc. |
PALO ALTO, Calif., May 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that the results from the randomized clinical study of canfosfamide (TELCYTA(R), TLK286) in combination
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 441 times since April 2007, the link to the organisation's website has been followed 86 times Recent Search Terms used to find this page: TELCYTA AND TELIK | Telik | telik componente .net | telik usa | . Search for more companies in Palo Alto Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Telik |
